ALung Technologies recently announced the initiation of patient enrollment in its VENT-AVOID trails with the Minneapolis Heart Institute Foundation. The trial is pivotal in validating the safety and efficacy of the Hemolung Respiratory Assist System for COPD patients who require ventilatory support.
Recent Posts
A Year in Review: A comprehensive look at UPMC Enterprises 2020
Over the last year, UPMC Enterprises, our portfolio companies, and select partners have all supported UPMC’s mission of Life Changing Medicine. In the booklet below, we have compiled highlights from a truly unique year and recognize the team members and projects that have enabled our success.
Read More →
Werewolf Therapeutics launches as publicly traded company
Werewolf Therapeutics, a biopharmaceutical company pioneering the development of therapeutics to stimulate the body’s immune …
Read More →
The Intersection of Value and AI: Where Machines Can Make a Difference
Upcoming CCM panel discussion features experts from UPMC, Vanderbilt, NCQA, and Astrata on the future of artificial intelligence in health care
Read More →